Menu Search
Equities

Oxford Biodynamics PLC

  • Add to watchlist
  • Add to portfolio
  • Add an alert
LMQ:STU

Oxford Biodynamics PLC

Actions
  • Price (EUR)0.001
  • Today's Change0.001 / 100.00%
  • Shares traded0.00
  • 1 Year change-75.00%
  • Beta2.8634
Data delayed at least 15 minutes, as of Feb 06 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Oxford BioDynamics Plc is a United Kingdom-based biotechnology company, advancing personalized healthcare by developing and commercializing precision clinical diagnostic tests for life-changing diseases. The Company is primarily engaged in the commercialization of proprietary molecular diagnostics products and biomarker research and development. Its products include EpiSwitch CiRT, EpiSwitch PSE, Specimen Submission Kit, and EpiSwitch Explorer. The EpiSwitch CiRT is a blood test which predicts an individual patient’s therapeutic response to checkpoint inhibitor immunotherapy. The EpiSwitch Explorer is a microarray kit for high-throughput, high-resolution 3D genome profiling. The Specimen Submission Kit is used for collecting samples from any location. The EpiSwitch platform offers reproducibly translating three-dimensional (3D) genome regulation for clinical applications. This platform provides a portfolio of clinical smart tests based on EpiSwitch technology.

  • Revenue in GBP (TTM)1.10m
  • Net income in GBP-11.15m
  • Incorporated2007
  • Employees44.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.